Development of ultrasound based molecular imaging in an attempt to predict early response of antiangiogenic therapy
| Project/Area Number |
21800055
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical systems
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
SUGIMOTO Katsutoshi Tokyo Medical University, 医学部, 助教 (20385032)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥2,353,000 (Direct Cost: ¥1,810,000、Indirect Cost: ¥543,000)
Fiscal Year 2010: ¥1,261,000 (Direct Cost: ¥970,000、Indirect Cost: ¥291,000)
Fiscal Year 2009: ¥1,092,000 (Direct Cost: ¥840,000、Indirect Cost: ¥252,000)
|
|---|
| Keywords | 造影超音波 / 分子標的がん治療薬 / 肝細胞癌 / 治療効果判定 / 分子標的バブル / ソナゾイド / ソラフェニブ / 分子標的イメージング |
|---|
| Research Abstract |
We conducted a study to determine the utility of contrast-enhanced ultrasonography (CE US) as a prognostic tool for advanced hepatocellular carcinoma (HCC) patients receiving sorafenib and to identify CE US parameters that correlate with early treatment response. As a results, CE US can be used to quantify dynamic changes in tumor vascularity as early as several days after sorafenib administration in patients with HCC. These early changes in tumor perfusion may be predictive of tumor response at 1 month, and they may be potential surrogate measures of the effectiveness of antiangiogenic therapy in patients with HCC.
|
Report
(3 results)
Research Products
(8 results)
-
-
-
-
-
[Journal Article]2009
Author(s)
杉本勝俊
-
Journal Title
Sorafenib投与後早期に代謝性脳症を併発し死亡した進行肝細胞癌の1例 50巻
Pages: 595-597
Related Report
Peer Reviewed
-
-
-
